Mochida and Fuji submit biosimilar G-CSF in Japan

Mochida Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. filed the first biosimilar G-CSF in Japan.

According to Fuji Pharma’s press release, the development of the product was started in February 2010 when Mochida made the joint development agreement with Gene Technology Co.

FKS0808 will be the first biosimilar G-CSF to be marketed in Japan and it will be marketed by a co-marketing strategy which means 2 brands and 2 channels.

Mochida’s interest in biosimilars were known before as they had signed an license and collaboration agreement with Gedeon Richter of Hungary last year. With that agreement, Mochida is obliged to make payments related to the fulfilment of certain regulatory criteria together with contributions to development costs while Richter is responsible for the global development of the biosimilar product line.

If you are interested in Japanese biosimilars market, following posts might be helpful for you:
- Japanese Biosimilars Guideline
- Japanese Biosimilars Market

Sources: 
1- Fuji Pharma press release
2- http://www.richter.hu/EN/Pages/pr101214a.aspx

Related posts:

1. Stada and Richter to co-develop rituximab and trastuzumab
2. Japanese Biosimilars Guideline
3. Japanese Biosimilars Market
4. Natco & Mabxience: another collaboration for biosimilar mAbs